

# END OF DAY NEWS WRAP

15:45 11 Sep 2017

## Proactive news snapshot: ANGLE, Jersey Oil & Gas, Mosman Oil And Gas ...

ANGLE PLC has established a co-marketing agreement with QIAGEN NV, a world-leading provider of molecular testing solutions. The AIM-listed liquid biopsy firm said the partnership will "seek to leverage the advantages of combining ANGLE's world leading Parsortix system for harvesting circulating tumor cells (CTCs) with QIAGEN's liquid biopsy solution portfolio".

North Sea focused Jersey Oil & Gas PLC (LON:JOG) has revealed that the Statoil operated Verbier exploration has been unsuccessful, finding the target reservoir to be water bearing and deeper-than-expected.

Mosman Oil And Gas Limited (LON:MSMN) has unveiled its latest acquisition in North America, picking up the Welch Permian basin project in West Texas in a US\$310,000 deal. The company said the project, located about 550 kilometres from Dallas, comprises ten existing production wells plus ten shut-in wells and seven injectors. It presently produces around 34 barrels of oil per day.

Drug discovery and development company Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) has secured up to US\$62m of funding from the US government. The Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, awarded the contract to support the clinical and regulatory development of ridinilazole for the treatment of the C. difficile infection (CDI), including Summit's planned Phase 3 development programme.

Rose Petroleum PLC (LON:ROSE) has announced that a binding stock purchase agreement (SPA) has now been signed with Magellan Gold Corporation in relation to the previously proposed deal for Rose's metal processing operation in Mexico.

Tlou Energy Limited (LON:TLOU) boss Tony Gilby has handed in his annual report card on what he called a "phenomenal year" for the company.

Michael Travia, managing director of fast-growing office productivity software group BOS GLOBAL Holdings (LON:BOS), has quit the company.

Silence Therapeutics PLC (LON::SLN) has gained further protection for its US patent estate with the announcement that the US Patent and Trade Mark Office has issued a notice of allowance for its patent application 15/594,438, and with a further key US patent to be granted tomorrow. The AIM-listed firm - a developer of novel RNA therapeutics for the treatment of serious diseases with unmet medical needs - said it has made the relevant payment of grant fees for US patent application 15/594,438 and normal practice is that the granted patent will now be issued by the US Patent and Trade Mark Office.

Atlantis Resources Limited (LON:ARL) noted that, as expected, its MeyGen Limited subsidiary was not awarded a 2071 contracts for difference allocation for renewable energy projects by the UK Department for Business, Energy & Industrial Strategy (BEIS). However, the AIM-listed tidal power generation firm it has commenced a dialogue with BEIS officials to "recognise the benefits of either a bi-lateral CfD discussion or the reintroduction of a marine energy sub-

### Share Information

#### MarketTopic Synopsis:

*The End of the Day Wrap provides a summary of the most interesting articles published by Proactive Investors during the day, including all of the main stories and exclusive interviews with executives.*

#### Author:

**Jon Hopkins**

**+44(0)1202770386**

**action@proactiveinvestors.com**

category in the next allocation round, either of which would be welcomed by Atlantis."

Be Heard Group PLC (LON:BHRD) saw "exceptional revenue growth" in the first half and expects the growth rate to pick up in the second half.

Genedrive PLC (LON:GDR), the molecular diagnostics company, said its Genedrive HCV ID kit has achieved CE certification under the EU Medical Devices Directive.

Seeing Machines Limited (LON:SEE) saw like-for-like revenues soar once again last year and the eye-tracking technology specialist has now set its sights on turning over US\$100m by the end of 2019. Like-for-like sales more than doubled in the year ended 30 June to A\$13.6m (2016: A\$6.1m), driven by another strong performance from its Guardian fleet division.

Allergy Therapeutics plc (LON:AGY) has strengthened its clinical research team with two senior appointments. Pieter-Jan de Kam joins as clinical director, while Simon Piggott will become head of clinical science.

Diversified Gas & Oil PLC 's (LON:DCOG) production surged in the half year to June as the recent package of 1,300 wells in the US contributed for the first time.

Ortac Resources Ltd (LON:OTC) has announced that from henceforth it will focus on two gold projects in Africa held as investments, Casa Mining and Zamsort. The move follows the appointments of Nick von Schirnding and Brian McMaster to the board and the passing of all resolutions at an AGM last week.

Goldplat PLC (LON:GDP) has issued an application out of the High Court of South Africa, Gauteng Local Division, Johannesburg, for the recovery of money owed to it by Rand Refinery Limited. It's a long-running dispute that dates back to a more troubled period in Goldplat's history. Goldplat has long since re-worked its corporate model to avoid such disputes in future.

NetScientific PLC (LON:NSCI) said its portfolio company, ProAxis today announced that it has signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, utilising its novel ProteaseTag® technology. The AIM-listed transatlantic healthcare IP commercialisation group said in a statement that ProAxis's unnamed partner is a large biotechnology company, headquartered in the US with a focus on developing new therapeutic options for patients with rare diseases.

Cancer drug developer Scancell Holdings Plc (LON:SCLP) presented the latest data from its Moditope platform at the International Cancer Immunotherapy conference in Germany - one of the most prestigious meetings in the industry's calendar. Moditope stimulates the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

Hummingbird Resources PLC (LON:HUM) has received £165,000 in cash as consideration for the issue of 750,000 new ordinary shares in the company, under the receipt of a notice of exercise in respect of 750,000 warrants, issued at the exercise price of 22p per share.

Providence Resources PLC (LON:PVR) shares took another big hit on Monday, after the Irish explorer revealed that the second and final target in its exploration programme was found to be water bearing. It follows a similarly disappointing result for the well's Druid exploration target. The Irish exploration well will now be being plugged and abandoned.

Faron Pharmaceuticals Ltd (LON:FARN) said non-executive director, Dr Jonathan Knowles, has bought 63,000 ordinary shares in the company at a price of 725p per ordinary share. Dr Knowles now holds 110,712 ordinary shares in the company.

Sphere Medical Holding PLC (LON:SPHR) has revealed that LSP Life Sciences Fund NV has disposed of its entire 7.7% stake in the company ahead of its plans to de-list from AIM and become a privately-held entity as part a condition of a £8m investment led by Neil Woodford.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.